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The use of human stem cells (SCs) in tissue engineering holds promise in revolutionising the treatment
of numerous diseases. There is a pressing need to comprehend the distribution, movement and role of
SCs once implanted onto scaﬀolds. Nanotechnology has provided a platform to investigate this
through the development of inorganic magnetic nanoparticles (MNPs). MNPs can be used to label
and track SCs by magnetic resonance imaging (MRI) since this clinically available imaging modality
has high spatial resolution. In this review, we highlight recent applications of iron oxide and
gadolinium based MNPs in SC labelling and MRI; and oﬀer novel considerations for their future
development.Mesenchymal stem cells
The twenty rst century has seen numerous scientic
discoveries in the eld of stem cell research which have led
us to broaden our understanding of cell biology. Stem cell-
based therapies are expected to have an important impact on
the treatment and cure of wide spread diseases such as dia-
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ollege London, Medical School, Rowland
wdell@ucl.ac.uk
at Nose and Ear Hospital, 330 Grays Inn
rchall@ucl.ac.uk
oxanne Hachani is currently a
hD student at University
ollege London, under the
upervision of Prof. Nguyeˆ~n TK
hanh, Dr Mark Lowdell and
rof. Martin Birchall. She
eceived her Bachelors of Science
n Biochemistry from the
niversity Claude Bernard Lyon
in 2010, and her Master of
cience in Nanoscale engi-
eering in 2012 from the Ecole
entrale de Lyon in collabora-
of Applied Sciences Lyon and
. Her current research projects
nanoparticles for labelling and
gineered scaﬀolds.
1373the rst in vivo transplantation of stem cell trachea implant
was successful,1 being able to track the stem cells in vivo
would allow us to monitor their biodistribution, viability in
tissue engineered organs and to understand their interactions
with the recipient's cells and the mechanical pathways
following transplantation.
Mesenchymal stem cells (MSCs) constitute a valuable pop-
ulation of SCs; they diﬀerentiate into cells of various tissue
types: cartilage, bone, muscle, ligament, tendon and adipose
(Fig. 1).2–5 Hence, understanding their molecular regulation and
their migration within scaﬀolds and in vivo is essential.6,7 The
use of stem cells in tissue engineering faces the challenge of
understanding the kinetics, distribution and function of the
cells aer transplantation.Dr Mark Lowdell is an assistant
professor at University College
London and Director of the
Laboratory of Cellular Thera-
peutics at Royal Free Hospital
London. His GMP facility
produces somatic cell medicines
and tissue engineered products
and he holds MHRA qualied
person status for their release
for clinical trials. Dr Lowdell's
has held and holds numerous
appointments to academic and
government advisory boards and is a member of the scientic
advisory boards of Cell Medica UK and Coronado Bioscience in the
USA. His team includes 9 GMP production scientists and 9 pre-
clinical research scientists.
This journal is ª The Royal Society of Chemistry 2013
Fig. 1 LineagepotentialofadulthumanMSCs.Thisﬁgure showstheabilityofMSCs
in thebonemarrowcavity to self-renew (curved arrow) and todiﬀerentiate (straight,
solid arrows) towards the mesodermal lineage. The reported ability to trans-
diﬀerentiate into cells of other lineages (ectodermand endoderm) shownbydashed
arrows remains controversial in vivo. Reproduced with permission from ref. 5.
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View Article OnlineThis reviewaims to investigate theuseofMNPsasa tool to label
and trackMSCs in vivo, aswell as exploring the possibility of active
targeting to increase the specicity of nanoparticle-labeled cells.Tracking stem cells by various imaging
modalities
Similar to molecular-based contrast agents, nanoparticles can
be used to enhance the resolution of imaging while oﬀering
better biocompatibility, toxicity and biodistribution. There areMartin Birchall is Professor of
Laryngology at UCL, London
and a practising airway surgeon.
He co-led teams which delivered
the worlds rst stem cell based
organ (trachea) transplants in
an adult (Lancet, 2008) and a
child (Lancet 2012), as well as
the world's second documented
laryngeal transplant. He has
over 150 peer-reviewed publica-
tions, including Lancet, Nature,
BMJ, and presently holds £8m in
peer-reviewed research grants.
This journal is ª The Royal Society of Chemistry 2013various imaging modalities clinically available: optical imaging,
magnetic resonance imaging (MRI), computed tomography
(CT), ultrasound (US), positron emission tomography (PET) or
single photon emission computed tomography (SPECT). Each
technique has its own advantages and drawbacks but
combining techniques can compensate for drawbacks in any
individual technique (Table 1).8–10 For example, a multimodal
nanoparticle can combine a uorescent probe, for high sensi-
tivity, and an MRI probe for high spatial resolution. Cellular
imaging with NPs can be a complementary tool to standard
molecular-based methods for the early detection of diseases,
understanding their processes, and is now developed more and
more to follow the eﬃcacy of therapy11 or labelled cells.
Nanoparticles (NPs) have potential as contrast enhancers in
medical imaging to track the implantation, retention and
migration of MSCs, which are necessary before cellular therapy
can be validated. NPs have a high surface area to volume ratio, a
property which can help control their biodistribution allowing
longer lifetimes for them to reach their targets, and the surface
chemistry can be adjusted to direct nanoparticle traﬃcking.
Recognition of targeted cells by specic receptors can be
achieved through optimising the surface properties of NPs and
its functionalisation by coupling targeting moieties which
recognise specic receptors of targeted cells.Nanoparticle-based cellular imaging
While there is a wide variety of imaging techniques used clini-
cally, diﬀerent factors must be considered when developing NPs
for SC tracking such as: sensitivity, resolution, specicity and
exposure of individual patients to secondary eﬀects (Table 2).
All these, when taken into account, lead to the selection of
techniques which are of clinical interest.8,21 In this review, we
will focus on MRI as this is most commonly studied for NP-
based stem cell tracking.Nguyeˆ~n Thi Kim Thanh FRSC
CChem CSci MInstP is a
Professor of Nanomaterials
and a Royal Society University
Research Fellow (http://
www.ntk-thanh.co.uk). She has
over 10 years of research
experience in synthesis and
biofunctionalisation of nano-
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tutes and scientic meetings.
She has served on organisation
and scientic committees for many major international confer-
ences on Nanoparticles research (e.g., Scientic chair of Faraday
Discussion 175:“Physical Chemistry of Functionalised Biomedical
Nanoparticle and organiser of UK Colloids 2014”. Recently she
edited a seminal book: “Magnetic nanoparticles: from fabrication
to clinical applications” published by CRC Press/Taylor and
Francis.
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Table 1 Comparison of several imaging modalities. Adapted with permission from ref. 9 and 10
Source of
imaging Spatial resolution
Tissue penetrating
depth Sensitivity Types of probe
Magnetic resonance
imaging (MRI)
Radiowave 25–100 mm No limit mM to mM (low) Para- (Gd3+) or
superparamagnetic (Fe3O4)
materials
Positron emission
tomography (PET)
g-ray 1–2 mm No limit pM (high) Radionuclides
(18F, 11C, 13N, 15O, 124I, 64Cu)
Computed
tomography (CT)
X-ray 50–200 mm No limit Not well characterized High atomic number atoms
(iodine, barium sulphate)
Optical uorescence
imaging
Visible or
near-infrared
light
in vivo, 2–3 mm;
in vitro, sub-mm
<1 cm nM to pM (medium) Fluorescent dyes, quantum dots
Table 2 Advantages and disadvantages of NPs in stem cell imaging
Advantages Disadvantages References
Multimodality Integrating several imaging functions on a single
platform. Recently, tri-modal imaging probes for MRI/
PET/optical imaging have been designed by combining
64Cu-DOTA chelates to MRI/optical imaging probes.
Non specic imaging of cells; reproducibility of
synthesis; interference of imaging modalities
12 and 13
Contrast Generating enhanced contrast (lipid-based NPs, Gd-
based NPs, iron oxide NPs)
There must still be enough nanoparticles to generate
suﬃcient contrast within a cell, while avoiding toxic
eﬀects.
14–17
Large surface
area to volume
ratio
Integration of larger amounts of contrast agents and
ability to control the circulation time of NPs Interaction with plasma proteins in vivo may alter the
nanoparticle's properties. Larger amounts of contrast
agents may lead to secondary eﬀects. Gadolinium
chelating ligands commercially available may be used
to functionalise the surface of NPs and prevent against
toxic side-eﬀects of free gadolinium ions such as:
– The disruption of any calcium-dependant reaction
(blockage of calcium channels, neurotransmission etc.)
since Gd3+ has a similar size to Ca2+
– Gd3+precipitates at physiological pH so this may
block the reticuloendothelial system (RES) by
impairing the phagocytic function of Kupﬀer cells.
18–20
Fig. 2 Commercially available Gd3+ chelate MRI contrast agents: (a) Gd DOTA,
(b) Gd DTPA, (c) Gd sulfonamide, (d) Gd b-galactosidase, (e) Gd esterase, (f) Gd
bpatcn-QD, (g) Gd glutamate. Reprinted with permission from ref. 85. Copyright
2010 American Chemical Society.
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View Article OnlineMagnetic resonance imaging (MRI)
MRI is amongst today's most studied imaging modalities for
cellular tracking and labelling as it presents numerous advan-
tages such as a high spatial15,16 and temporal resolution, and the
use of non-ionizing radiation.
In medical applications, MRI detects the signal of the
protons present in water, which will respond to a magnetic eld
in an environment-dependant manner (i.e. diﬀerent tissues).
Contrast agents are used to enhance the sensitivity by inu-
encing the relaxation time of the protons aer application of a
radiofrequency pulse, and this can be done in two ways. In an
isotropic system without any chemical exchange: longitudinal
or spin-lattice relaxation (T1) and transverse or spin–spin
relaxation (T2).
MRI positive contrast agents (T1)
Contrast agents for longitudinal relaxation of protons mainly
comprise of paramagnets as these possess a large number of
free electrons (lanthanides for example) and shorten T1, thus11364 | Nanoscale, 2013, 5, 11362–11373 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineforming bright contrast. This is the case of gadolinium-based
chelates which are clinically used as contrast agents (Fig. 2).17,22
However, precaution must be taken when using contrast
agents containing gadolinium because of recent cases of
nephrogenic systemic brosis (NSF) in patients with renal
failure who were administered Omniscan.13
This is why gadolinium cations Gd3+ are chelated when
administered to prevent toxicity. Complexes of Gd3+ are now
widely used in routine MRIs and can be conjugated with NPs to
render these applicable to T1 MRI imaging.23 These chelating
ligands are commercially available and they aim to prevent toxic
side-eﬀects of free gadolinium ions (Table 2).
The complexes which chelate Gd3+: DOTA (1,4,7,10-tetraa-
zacyclododecane-1,4,7,10-tetraacetic acid) and DTPA (diethyl-
enetriaminepentaacetic dianhydride) are stable and soluble in
physiological medium. They have a low osmotic potential and
are rapidly eliminated from the body by renal excretion, so this
confers the minimal biological impact desired.
Although DTPA was the rst chelate to be commercially
available, DOTA is preferred to DTPA. Indeed, it is more
advantageous in terms of high relaxivity, blood clearance rate
in vivo, higher binding coeﬃcient to Gd3+ (more stable in vivo in
terms of thermodynamics and kinetics) and for the same image
quality a smaller dose is required than DTPA.24
The main drawback of using this contrast agent is that it
must be administered in high concentrations to produce an
eﬀective contrast. This is because of diﬀusion, low relaxivity (the
change in relaxation rate) per gadolinium ion and dilution
phenomena in vivo aer injection. This is where the nano-
particles are benecial because they increase the quantity of
contrast agents per NP allowing a higher concentration of
contrast agent. They can also potentially lead to an easier tar-
geting as it is the case in tumours with passive targeting by the
enhanced permeability and retention (EPR) eﬀect. A recent
study also conrmed the use of gadolinium not only to labelTable 3 Comparison of some nanoparticles with high transverse relaxivity for T2 M
Nanoparticle Core size (nm)
H
d
Ferumoxide (feridex) gFe2O3,
Fe3O4 – dextran
4.96 16
Ferucarbotran (resovist) Fe3O4 –
carboxydextran
4 60
Fe3O4–PEG–(NH2)2 12 49
Fe3O4 9
gFe2O3 – alendronate 10 32
gFe2O3 – neridronate 10 38
gFe2O3 – zoledronate 10 37
gFe2O3 – risedronate 10 28
Fe3O4-casein 15 30
Fe3O4-dimercaptosuccinic acid 9.2 70
Fe3O4-dextran 20–25 91
Fe3O4-triethylene glycol 11
Fe3O4-(1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[methoxy(polyethylene glycol)]
copolymer)-mPEG1000
14 28
This journal is ª The Royal Society of Chemistry 2013MSCs but also to determine their viability aer transplantation
depending on the signal obtained.25MRI negative contrast agents (T2)
Several types of NPs including superparamagnetic iron oxide
nanoparticles (SPIONs) and ultra small SPIONs (USPIOs) were
developed in the 1980s and have now been clinically approved
by the EMA (European Medicines Agency) and FDA (Food and
Drug Administration). Negative contrast can be provided by
superparamagnetic iron oxide NPs which shorten the T2 relax-
ation time and produce a darker image. Two principal factors
play a role in the contrast enhancement: the iron oxide core and
its coating. The shortening of T2 is determined by transverse
relaxation of hydrogen protons of water molecules surrounding
the superparamagnetic iron oxide NPs.26
Iron oxide NPs have proven particularly useful by their
biocompatibility.27–30 The proton relaxation per atom due to
iron is greater than the one which can be attributed to para-
magnetic elements such as gadolinium, hence smaller amounts
of contrast agent can be administered. For in vivo applications,
superparamagnetic nanoparticles also present the advantage of
being magnetic only in the presence of an external magnetic
eld, and it has been proven that iron oxide is safely degraded
and metabolised by living organisms.31,32Imaging properties of MNPs depend on their
physicochemical characteristics
The MRI contrast enhancement by magnetic nanoparticles is
dependent on their composition, size, surface properties and
degree of aggregation (Table 3). It has been demonstrated for
example that size is a critical parameter inuencing the
transverse relaxivity r2,33,34 while the surface contact inuences
the longitudinal relaxivity r1.35 This is conrmed by theR imaging
ydrodynamic
iameter (nm) r1 (mM
1 s1) r2 (mM
1 s1) Ref.
0 10.1 120 27
(0.47 T) (0.47 T)
186 27
22 (1.5 T) 191 (1.5 T) 74
265 (1.5 T) 56
.5 — 287 (4.7 T) 75–77
.1 — 277 (4.7 T)
.5 — 254 (4.7 T)
.8 — 267 (4.7 T)
— 273 (3 T) 78
18.5 (1.5 T) 317 (1.5 T) 79
320 80
9.5 (1.5 T) 337 (1.5 T) 81
.6 385 36
(0.47 T)
Nanoscale, 2013, 5, 11362–11373 | 11365
Fig. 3 Advantages and limitations of current imaging modalities available
clinically. Reproduced from ref. 40 with permission from the Royal Society of
Chemistry.
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View Article Onlinequantum-mechanical outer sphere theory which expresses the
T2 relaxivity constant of iron oxide NPs26,36 such as:
1/T2 ¼ (256p2g2/405)V* Ms2a2/D(1 + L/a)
where g is the gyromagnetic ratio, V* the volume fraction of the
iron oxide core,Ms the saturationmagnetization, a the radius of
iron oxide core, D is the diﬀusion coeﬃcient of water molecules
and L the thickness of impermeable surface coating. The
transverse relaxivity depends on exchange between protons of
water molecules and outer shell electrons but also on electron–
electron interactions in the crystal structure of the nano-
particles, hence the importance of the iron oxide core size.
On the other hand, the shortening of T1 depends solely on
the direct exchange of energy between hydrogen protons in
water molecules and the paramagnetic element's outer shell
electrons, hence an indirect correlation with the surface of NPs.
Clinical MRI (1.5 T scanners with radiofrequency coils) is not
ideal for imaging of single cells aer systemic administration.
The spatial resolution needed would require long scanning
times, which is not feasible in clinical settings. The latter are
still adequate for magnetically labeled cells administered locally
(for example, in the case of an implanted scaﬀold). This
requires a compromise between the minimum number of cells
detectable and the concentration of NPs to ensure there is no
eﬀect on cell viability or proliferation. Scha¨fer et al. recently
determined that at least 1000 SPIO-labelled MSCs could be
visualised byMRI in vitro aer exposition to a magnetic eld.37 A
recent study showed that a relatively high incubation concen-
tration (10 mg USPIOs per 105 cells) and long incubation times
(21 h) were needed to detect a minimum of 250 000 MSCs
in vivo.38 Most notably, in comparison, the in vitro detection
threshold of cells aer incubation with gadolinium oxide
nanoparticles at a Gd concentration of 0.2 g per 5  105 cells for
2 h was estimated to be about 10 000 cells.39 Yang et al. were
able to compare the eﬃciency of MSC labeling with SPIONs and
paramagnetic chelates. Iron oxide nanoparticle labeling had a
detection threshold of 12 500 cells in vitro, while gadolinium
chelates labeling could be detected for at least 50 000 cells.40
New strategies have been explored to overcome the limits of
clinical MRI when studying the biodistribution of a single cell.
These include the use of high eld MRI scanners (for example
9.4 T, 17.6 T),41 cryogenic probes,15 or high temperature super-
conducting coils16 that can bemounted on clinical 1.5 T devices,
which allow the resolution at a single cell level even aer
systemic administration.
MRI is a high resolution-low sensitivity technique leading to
a near cellular resolution (25–50 mm). Current research focuses
on its combination with other higher sensitivity-low resolution
techniques such as Positron Emission Tomography (PET),
Single Photon Emission Computed Tomography (SPECT) or
NIRF imaging (Near Infrared Fluorescence).
Indeed, multimodal nanoparticles incorporating several
imaging probes on a single platform are being developed. This
is to overcome the limitations of a single modality by com-
plementing it with another modality (Fig. 3).42 The main
disadvantages of MRI currently are the loss of signal with time11366 | Nanoscale, 2013, 5, 11362–11373and the lack of specicity. Nanoparticles can be taken up by non
specic cells in vivo aer implanted stem cells undergo
apoptosis or degradation, or their exocytosis can occur under
stress conditions.43–46 To overcome these limits, chitosan coated
NPs have been developed as they allow an enhanced uptake and
long term tracking of cells through limited endo-lysosomal
traﬃcking and exocytosis.47,48 Recently, hydrophilic SPIONs
coated with glucosaminic acid (GA) were shown to enhance
cellular uptake of NPs.49 Furthermore, once the MSCs divide or
diﬀerentiate the concentration of nanoparticles decreases
rapidly hence the MRI signal is lost with time. Encapsulation of
iron oxide nanoparticles in polymeric microparticles has been a
new strategy explored to help maintain a strong MRI signal and
reduce exocytosis in order to enable the longitudinal tracking
of SCs.Nanoparticles for in vivo tracking of
transplanted MSCs
NPs are fabricated from diﬀerent building blocks which can be
organic (e.g., polymeric micelles, dendrimers) or inorganic (e.g.,
iron, gold, silver, silica). It is now relevant to present some of the
most common NPs currently studied for the tracking of MSCs.
Although several contrast agents that have been clinically
approved and tested, nanomaterials are gaining more attention
since their properties (size, shape, surface chemistry.) can be
nely tuned for specic applications.50,51
Indeed, quantum dots (QDs) which are semiconductor
nanocrystals, are frequently used for cellular optical imaging.
QDs exhibit a size-dependent uorescence emission wave-
length, enhanced photo-stability properties making them the
ideal tools for long term cell labelling and tracking.52 PEG
coated CdSe/ZnS QDs were used to label MSCs transplanted inThis journal is ª The Royal Society of Chemistry 2013
Fig. 4 Structure of polymeric stabilizers of magnetic nanoparticles (a) PEG, (b)
PVA, (c) PEI, (d) chitosan, (e) dextran, (f) pullulan, and (g) alginate. Reprinted with
permission from ref. 65. Copyright 2012 American Chemical Society.
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View Article Onlinenude mice in 2008 by Lei et al.53 24 h aer transplantation, the
QDs- hMSCs were visualised under uorescence imaging
showing signicant accumulation in the liver, lung and spleen.
More recently, they were used to label and image rat pancreatic
stem cells and were once again proven to have no eﬀects on cell
viability and proliferation.54 However, all studies have been
done in animal models as there is great concern in regards to
the toxicity of QDs through their degradation and the release of
cadmium in vivo.
Magnetic ferrite NPs have also been studied for cellular
labelling, but to a lesser extent. Indeed, rat neural stem cells
labelled with the CoPt hollow nanoparticles were injected into
cultured spinal cord slices and observed over time.55 This study
indicated thatMRl can eﬀectively detect low numbers of labelled
cells due to the enhanced contrast provided by the cobalt-based
nanoparticles which provide a stronger response to magnetic
elds than iron oxide for example. While the NPs are eﬃcient
tools for MRI and are biologically stable for long periods of time,
the problem of introducing platinum in vivo needs to be
addressed before clinical applications may be pursued.Fig. 5 In vivo and ex vivo visualization of SPION-labeledMSCs. In vivoMR imaging
showed areas of hypointensity in rat muscle tissue in the axial (A; a and c) and
sagittal (A; b and d) view albeit with a larger area of hypointensity seen for citrate
SPION-labeledMSCs (A; a and b) than for Endorem SPION-labeled cells (A; c and d).
Consistently, transplanted citrate SPION-labeledMSCs showed considerably higher
hypointense volume and surface area compared to Endorem SPION-labeled cells
(B). Reprinted from ref. 69, Copyright (2012) with permission from Elsevier.Iron oxide NPs
Amongst magnetic nanomaterials, manganese ferrite NPs
possess the highest magnetic moment per unit, making them
the nanosystems with the highest transverse relaxivity amongst
ferrites.56
However, iron oxide NPs have been coveted as multifunc-
tional imaging and therapy tools because of their biocompati-
bility and their well-known chemical synthesis57 which leads to
a highly uniform and crystalline structure. As mentioned
previously, SPIONs and USPIOs are available commercially for
clinical applications, hence increased research focus on these
particles.
Some iron oxide-based NPs commercially available or
recently developed in research laboratories are listed for eﬃ-
cient T2 contrast comparison (Table 3). Iron oxide NPs such as
magnetite (Fe3O4) or its oxidized form maghemite (g-Fe2O3) are
currently the most studied systems for cellular labelling and
biomedical imaging. Indeed, their non-toxicity and non-
immunogenicity is essential for pre-clinical and clinical use.
Due to their clinical approval, commercial iron oxide NPs
have been used to label and track various types of stem cells
aer their transplantation such as bone marrow stromal stem
cells,58 embryonic stem cells,59 neural stem cells,60,61 hemato-
poietic progenitor cells.62–64 Sykova´ and Jendelova´ have shown
that the use of Endorem can be used eﬀectively to track the
migration of transplanted mouse embryonic stem cells (ESC) to
sites of injury by MRI over extended periods of time.65
A study in 2012 showed that in comparison to Gd chelates,
iron oxide NPs did not allow the diﬀerentiation of viable or dead
cells, thus leading to a misleading MRI signal.25 Also, Bos et al.
in 2004 showed that while SPIO labelled MSCs injected in rat
kidney and liver were able to diﬀerentiate properly, above
100 mg Fe ml1, their proliferation was decreased.66 This is
something to consider for long term imaging of cells and their
migratory capacity aer transplantation.This journal is ª The Royal Society of Chemistry 2013These FDA-approved NPs have now all been discontinued
and a variety of SPIONs are developed with physico-chemical
properties which may be nely tuned.
The hydrophobic nature of SPIONs implies that their surface
must be rendered stable and biocompatible by coating with
biomolecules or polymers such as dextran, polyethylene glycol
(PEG), citrate and chitosan (Fig. 4).67 The coating will inuence
the imaging properties of the NP as it may hinder the diﬀusion
or interaction with water molecules. In addition, the coating
minimizes non-specic interactions and prevents aggregation
of the iron oxide cores.
Dextran is a polysaccharide commonly used to stabilise iron
oxide nanoparticles as it has been shown to have a particular
aﬃnity for their surface through hydrogen bonding.68,69
However, several years ago, it was demonstrated that aer
incubating hMSCs with dextran coated nanoparticles during 2
hours at 25 mg Fe ml1, no labeling of hMSCs was detectable.
More recently, Babicˇ and colleagues also conrmed the low
aﬃnity of dextran coated iron oxide nanoparticles and rat
MSCs, even aer long incubation times of up to 72 h with
rat MSCs.70
The coating of NPs is essential as proven by K. Andreas et al.
who recently conrmed an increased cellular uptake and more
intense MRI hypointensity of citrate SPIONS compared to
commercial SPIONs at the same iron concentration (Fig. 5).71
Recent research has studied the increased cellular uptake of
negatively charged NPs with an increased density of carboxylNanoscale, 2013, 5, 11362–11373 | 11367
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View Article Onlinegroups, which probably occurs through electrostatic adsorption
on negatively charged cellular membranes.72
Labelling of hMSCs has been successfully achieved with
magnetic iron oxide silica core–shell nanoparticles.73 These
nanostructures allow bimodal imaging with the incorporation
of the organic dye uorescein isothiocyanate (FITC) in the silica
shell. The high labelling eﬃciency was demonstrated with the
need for a short incubation time of 1 h and a low concentration
of iron (0.5 mg ml1).
No cytotoxicity was present aer incubation, thus cells
preserved their diﬀerentiation abilities and imaging of low
number of cells (105) was possible with a clinical grade 1.5 T
MRI imager.
More recently, ultra magnetic liposomes have been con-
structed with a highly eﬃcient encapsulation and concentration
of ultra- small iron oxide nanoparticles inside a liposome.82 This
structure possesses a high blocking temperature, enhanced
heating properties for hyperthermia and a high r2 value leading
to better contrast in MRI. Another recent study was conducted
with ‘nanoowers’ constituted by multi-core NPs made of
maghemite cores.83,84 The three-dimensional organization of
the cores with their close spherical contact, identical crystal
orientation and the absence of a matrix lead to cooperative
behaviour. This in turn leads to an enhanced magnetic moment
and r2 relaxivity while maintaining the hydrodynamic diameter
below 40 nm which is ideal for biological applications.
In regards to MRI, these nanostructures are potentially eﬃ-
cient as it was demonstrated single tumour cells could still be
distinguished 6 days aer they had been labelled.
Gadolinium based NPs
As positive MRI contrast agents, Gd-based NPs have been less
studied than iron oxide NPs for labelling of stem cells. Recently,
Shi and colleagues have used 6 nm anionic europium (Eu3+)
doped Gd2O3 nanoparticles for bimodal labelling and imaging
of hMSCs.39 Europium provides a uorescence signal whereas
the oxide core constitutes a positive CA for MRI with a relaxivity
value r1 ¼ 13.2 mM1 s1, which is greater than that of
commercially available Gd-chelates. While the labelling had no
negative eﬀect on cell viability and diﬀerentiation, no studies
were conducted to determine the fate of these NPs within the
cells and over time.
The coating also plays an important role in the MR tracking
of cells by inuencing the relaxation properties of the NPs.
Indeed, it has been shown that the transfer of gadolinium oxide
NPs from an organic solvent such as diethylene glycol (DEG) to
capping with a PEG chain allows a signicant increase of the
longitudinal relaxivity constant.85,86
Tracking stem cells using magnetic nanoparticles (MNPs)
Tracking SCs in vivo has been hindered by the inability to nd a
suitable imaging technique for obtaining dynamic information
and cellular resolution during several days or weeks in a non-
invasive manner. Recently, MRI has become a well-studied
technique for imaging SCs at a quasi-cellular level by labelling
with iron oxide NPs. While this has been studied on human11368 | Nanoscale, 2013, 5, 11362–11373MSCs in vitro or on animal SCs in vivo,66,87 few studies have yet to
report reliable results on labelling hMSCs in vivo within tissue-
engineered scaﬀolds.
Pre-clinical studies have largely been restricted to small
rodents. For example in 2002, Modo et al. studied the trans-
plantation of stem cells in ischemia-damaged rat hippocampus
by MRI.88 However, these cells successfully migrated and inte-
grated the host's parenchyma and it was challenging to diﬀer-
entiate these from the host cells by MRI hence the need for
labelling with an eﬃcient contrast agent allowing identication
of small clusters at high resolution. While gadolinium
rhodamine dextran was an eﬃcient T1 and T2 contrast agent
(r1 ¼ 17 mM1 s1), the uorescence signal was lost aer 7 days
due to dilution of the signal following division of the cells. The
dual imaging allowed detection of the cells by overlaying
histology and MRI without need for another technique.
Lee and colleagues labelled hMSCs with commercial uo-
rescent NPs (NEO-LIVE Magnoxide 675) and monitored their
movement from inside the bone marrow cavity of rats to an
osteochondral defect for up to 21 days.42,89 This allowed them to
conclude on the eﬃcacy of platelet-derived growth factor
(PDGF-AA) as a chemotactant for hMSCs.
Most notably, the novel approach of labelling stem cells
in vivo was successfully achieved by Heike Daldrup-Link's team
by injecting ferumoxytol, an FDA-approved anemia treatment
composed of iron oxide nanoparticles within the bone marrow
of rodents. The mesenchymal stem cells were then injected into
knee injury sites of rats, and were visualised over several
weeks.90 This new strategy has yet to be tested with humans but
holds great promise for the development of stem cell therapies.
Indeed, this would decrease substantially risks of contamina-
tion and biologic alteration of MSCs associated with ex vivo
labelling procedures.Challenges and future considerations
The main challenge to overcome is the dilution of signal due to
cell division and exocytosis of the NPs. In cell populations
which divide rapidly, such as hMSCs, NPs will be distributed
evenly or unevenly amongst daughter cells. Aer few cycles of
cell division, only a fraction of the cell population is labelled
and the signal becomes undetectable. A way to overcome this is
to genetically transfect the cells to express certain reporter
genes such as the Green Fluorescent Protein (GFP) for uores-
cence imaging or luciferase for bioluminescence. This has been
widely employed in pre-clinical animal studies. However, the
eﬀect of genetically modied cells in humans has to be estab-
lished before thinking about potential clinical applications.
Research regarding the impact of magnetically labelled
human MSCs on chondrogenesis remains insuﬃcient. This
must be carefully studied as SCs are long-lived cells that will
persist and divide in vivo. While many groups have shown that
there is no negative impact on the diﬀerentiation of human
MSCs,91,92 some have shown impaired chondrogenesis.93–96
Whilst not yet been fully understood, it could be due to a dose-
dependent disruption of iron metabolism involved in chon-
drogenesis and interference with the organisation of theThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinecytoskeleton. This has been demonstrated with the inhibition of
osteogenesis and the promotion of cell migration aer labelling
hMSCs with Ferucarbotran, an ionic SPION clinically approved
as a contrast agent for MRI of the liver.97 The inhibition
occurred in a dose-dependent manner and could be correlated
to the presence of free irons following the lysosomal degrada-
tion of the nanoparticles.
To overcome the problem of dilution of the contrast agent
signal due to cell division and exocytosis of the NPs, a recent
report illustrated the eﬃciency of encapsulating 10 nm iron
oxide NPs within poly(lactide-co-glycolide) microparticles of
0.8 mm in diameter.98 Indeed, this system allowed a 5-fold
increased r2 relaxivity (from 61.16 mM
1 s1 to 316.6 mM1 s1)
and2-fold increased retentionwithinMSCs compared to the iron
oxide NPs alone. Aer 18 days, only microparticle-labelled cells
showed uorescence in more than 15% of cells whereas nano-
particle-labelled cells no longer emitted a uorescence signal.
This was also the case of the MRI signal which allowed visuali-
zation of the microparticles 12 days aer labelling, and of
nanoparticles only up to 6 days. These enhanced properties
could be to a size-dependant exocytosis which is slower for larger
particles and a clustering of the NPs within the microparticles.
As discussed, imaging is useful as a non-invasive method of
tracking MSCs in vivo to comprehend the underlying processes
essential to the development of tissue-engineering based ther-
apies. The nanosystems must be sensitive, non-toxic, hydro-
philic, non-immunogenic and must be cleared through the
renal system. These MNPs which can be used for multimodal
imagingmay be further functionalized towards imaging specic
targets such as a dened cell type for example.Strategies for active targeting of
transplanted MSCs
Composition, size, morphology and surface chemistry can now
be tailored to improve magnetic properties but also aﬀect the
behaviour of MNPs in vivo.99,100 Biomedical applications require
stability in physiological conditions. Modifying the surface's
chemistry is essential for their colloidal stability, biocompati-
bility, and to avoid aggregation in vivo.101 Cell surface labelling
is not ideal for in vivo applications due to potential recognition
by the RES and their subsequent clearance, hence the interest in
functionalizing the surface of NPs to increase their cellular
uptake, to yield specic recognition by MSCs and to minimize
their recognition by the RES. Active targeting strategies will vary
according to the applications desired. For example for cancer, it
is a common strategy to gra a vector on the NP that will bind to
a receptor or biomarker strongly overexpressed by cancer cells.
The aim is to increase selectivity by tumour cells, minimize
secondary eﬀects on healthy cells therefore decreasing the dose
and impact of treatments administered.Targeting of NPs depends on their
physicochemical properties
Fundamental properties such as the size and shape of NPs will
inuence their ability to target specic cells. In a recent study byThis journal is ª The Royal Society of Chemistry 2013Jiang et al., multivalent graing of herceptin on NPs of 2
diﬀerent sizes was engineered to allow the recognition of the
ErbB2 receptor overexpressed on human breast cancer cells.102
While very small NPs (#25 nm) had a good biodistribution they
did not allow the presentation of multiple ligands to the cell
receptors. This could be achieved with larger NPs ($50 nm) and
with a higher binding aﬃnity. A compromise between the bio-
distribution and binding ability can be achieved with NPs of
average size 25–50 nm.
In addition, the shape of the NPs will inuence their tar-
geting ability. Several studies have demonstrated that relative to
targeted spherical NPs, rod-shaped NPs will have a longer blood
circulation time and enhanced cell binding properties.103–106
The surface plays an essential role in the biocompatibility
and stability of NPs in vivo. In the case of iron oxide NPs,
dextran is a polysaccharide oen used for coating because of its
biocompatibility and high aﬃnity for the surface of iron oxide
NPs by polar interaction through hydrogen bonding for
example.69 However, labelling of hMSCs with dextran coated
NPs has proven diﬃcult without the use of transfection
agents.70,107 A frequently used polymer is polyethylene glycol
(PEG) which renders the NPs hydrophilic and extends their
blood circulation times by steric repulsion of opsonins.108,109
This polymer is non toxic, non immunogenic and has been
approved for clinical applications.Transfection agents to increase cellular
uptake of MNPs
Due to the limited phagocytic capacity of MSCs a poor cellular
uptake of commercially available MNPs leads to limited MRI
sensitivity. MNPs are highly phagocytized by Kupﬀer cells of the
RES, thus diﬀerent surface modication strategies have been
explored to increase their cellular uptake.110 The cellular uptake
of NPs will depend on the size, shape and surface chemistry of
NPs, but also on the cell line. A strategy widely studied is the use
of transfection agents which oen are positively charged
peptides to facilitate the internalization of NPs by cells.
However, this requires a purication step of the cells to mini-
mize non-specic uptake by other cell populations in vivo. Also,
they may pose the problem of toxicity if their ratio is not
controlled and if used on their own.111,112 The HIV Tat peptide
has been conjugated to dextran-coated iron oxide NPs to
increase cellular uptake.113,114 More recently, Ferucarbotran was
labelled with protamine sulphate during a 4 h incubation
period thus increasing the internalization of NPs by hMSCs.95
Ferumoxide and protamine sulphate have also been used to
label hMSCs for imaging of the cells over 12 weeks.115 This study
has led to a better understanding of the homing of hMSCs aer
their local intra-articular injection.Active targeting of MNPs to MSCs
To gain in specicity, reduce side eﬀects and toxicity, active
targeting is done by linking biomolecules on therapeutic
vectors, such as MNPs, to recognise receptors on specic cells.
The receptor must be accessible (at the surface and close toNanoscale, 2013, 5, 11362–11373 | 11369
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View Article Onlineblood stream), specic to the stem cell, and recognised by a
ligand of strong aﬃnity and specicity. In the case of an anti-
body, the availability of internalizedmonoclonal antibodies and
the limited number of cell membrane receptors must be
addressed.
MSCs have been identied through their expression of
specic cell surface markers such as the following clusters of
diﬀerentiation, CD73, CD90, CD105 (endoglin, SH2), CD106
and CD309.116–118 The latter is also known as the vascular
endothelial growth factor receptor or KDR. In contrast to
hematopoietic stem cells, they do not express CD45, CD34, and
rapidly down regulate CD133 upon culture. However, the
expression of cell surface markers is complex and not yet fully
understood as it may be inuenced by factors secreted by
accessory cells in the initial passages, and the in vitro expression
of MSC markers may diﬀer with their expression in vivo119 as
well as their diﬀerentiation stages.
Being able to target specic markers would allow us to gain a
deeper understanding on the evolution and becoming of hMSCs
once transplanted. Furthermore, this would allow targeted
labelling of MSCs in vivo. As mentioned previously, the novel
approach of actively targeting SCs in vivo has yet to be investi-
gated although it would help minimize alteration of MSCs. This
approach has been demonstrated successfully with endothelial
progenitor cells labelled with CdSe quantum dots and their
diﬀerentiation into mature endothelial cells within a vascular
bypass gra being followed by optical imaging.120 Also, speci-
cally targeting surface markers of MSCs may be useful for
tissue-engineered scaﬀolds which are seeded with selected and
isolated cell populations, thus minimising non specic inter-
actions with other cell populations which may occur in vivo.
It has been shown that hMSCs play an essential role by
mobilizing into the peripheral blood when needed or migrating
across endothelial cells from the blood into tissues. Angiogen-
esis requires migration and adhesion of endothelial cells on the
extra cellular matrix (ECM) to form new blood vessels. This
phenomenon requires adhesion molecules such as integrins
which are heterodimeric transmembrane cell surface receptors
which participate in cell–cell and cell–ECM interactions. They
link cells to their surroundings and to proteins of the ECM
(collagen, laminin, bronectin.). Various integrin molecules,
such as a1, a2, a3, a4, a5, av, b1, b3, and b4, are known to be
expressed on hMSCs. Adhesion molecules such as VCAM-1,
ICAM-1, ICAM-3, ALCAM, and endoglin are expressed on this
cell line.121
The strategy of using nanoprobes to target specic cells has
yet to be explored for mesenchymal stem cells, but has been
thoroughly investigated for tumour cells. Indeed, active target-
ing of cancer cells has been developed with multimodal
nanoprobes functionalized by the cRGD peptide. The tripeptide
RGD (Arginin – Glycin – Aspartate) is present in numerous
proteins of the ECM and is a ligand of the integrin avb3 which is
specically upregulated by tumour endothelial cells for angio-
genesis. The aﬃnity is related to the protein's conformation.
The integrin avb3 has an extracellular V-type structure in which
each subunit has a “closed headpiece bent” conformation.
Physiologically, it corresponds to a weak aﬃnity state. The11370 | Nanoscale, 2013, 5, 11362–11373xation of a ligand, such as the RGD peptide, will lead to a
conformational change in which the aﬃnity is increased. Then
we obtain the activated receptor in which the cytoplasmic
domains are far. Cyclic peptides are more oen used than the
linear equivalent since the latter was shown, in clinical trials, to
accumulate strongly in the liver and not in the desired tumour
cells.122 Also, the linear form of the peptide can have confor-
mations with diﬀerent aﬃnities for the integrin avb3 and are
more sensitive to proteolysis.
The team of J. L. Coll and P. Dumy was able to target the
integrin avb3 with the target peptide RAFT(c-[RGD])4.123 The
interest of polymers like the RAFT peptide is the possibility to
present multiple copies of the RGD peptide. It has a better
aﬃnity towards the integrin avb3 (known to prefer multivalent
interactions), improved target internalization in cells, and
better signal to noise ratio in vivo.
Recently, active targeting of tumour cells using RGD func-
tionalized nanoparticles has been developed for targeted drug
delivery as specic targeting was shown to be eﬃcient in
numerous studies.124–127
However, the idea of targeting specic cells by surface
markers remains a challenge. While surface markers of specic
cells can be determined, their specicity remains the bottleneck
of this issue. This may not raise concerns when dealing with an
isolated cell population however in vivo applications require
further study into identifying specic surface markers to target.Conclusions
Iron oxide-based NPs have been extensively studied for the
labelling and MR imaging of hMSCs. However, positive contrast
agents such as gadolinium-based NPs hold great promise as a
non-invasive and eﬃcient imaging tool. Both nanoparticles
remain interesting by the ability to tune their magnetic prop-
erties and surface chemistry. Novel multimodal NPs also allow
the use of MRI in complement to other imagingmodalities such
as PET, SPECT or optical imaging to overcome the limits of MRI.
The latter includes the need for high concentrations of contrast
agent administered to obtain suﬃcient contrast,55 which is a
key point explored for the development of future nanoprobes in
cell labelling and imaging. However, further studies need to be
conducted to address questions which remain before clinical
applications of stem cell therapy can be considered.Outstanding questions
While this review focuses on targeted imaging of hMSCS, some
general questions remain regarding nanoparticle-based cell
tracking:
 How to maximize the labeling eﬃciency of hMSCs with
various NPs and minimize non-specic uptake of NPs by other
cell populations?
How to gather functional information about the MSCs once
administered?
 What happens to the nanoparticles inside the cells?
How do we monitor the change of the nanoparticles within
the cells?This journal is ª The Royal Society of Chemistry 2013
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View Article Online Which characteristics of the nanoparticles can we modify
so they can remain in the cells long enough and be eliminated
safely aerwards?
 How can we obtain quantitative information from the im-
aging output?
 What do we need to prove in terms of toxicology to estab-
lish nanoparticles as a safe means by which cells can be labelled
and tracked in vivo?Acknowledgements
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